Roflumilast

Roflumilast cream is used for the treatment of plaque psoriasis and atopic dermatitis, while roflumilast foam is used for the treatment of plaque psoriasis and seborrheic dermatitis, to improve itching and inflammation and control skin symptoms. Roflumilast is a once-daily, steroid-free cream or foam that can be used long-term anywhere on the body, including sensitive areas such as the face or skin folds, and hairy areas. Roflumilast is well tolerated, with very little stinging or burning. Roflumilast brand name is Zoryve. Roflumilast is also available as a tablet for COPD (chronic obstructive pulmonary disease) under the brand name Daliresp . Roflumilast mechanism of action (MOA) is by inhibiting the enzyme PDE4 , an enzyme that plays an important role in controlling inflammation and immune responses in the body. By inhibiting PDE-4 (Phosphodiesterase-4), roflumilast helps to reduce redness, itch, scaling, and improve other skin symptoms. Roflumilast is a phosphodiesterase 4 (PDE4) inhibitor.

Roflumilast cream is used for the treatment of plaque psoriasis and atopic dermatitis, while roflumilast foam is used for the treatment of plaque psoriasis and seborrheic dermatitis, to improve itching and inflammation and control skin symptoms. Roflumilast is a once-daily, steroid-free cream or foam that can be used long-term anywhere on the body, including sensitive areas such as the face or skin folds, and hairy areas. Roflumilast is well tolerated, with very little stinging or burning. Roflumilast brand name is Zoryve. Roflumilast is also available as a tablet for COPD (chronic obstructive pulmonary disease) under the brand name Daliresp . Roflumilast mechanism of action (MOA) is by inhibiting the enzyme PDE4 , an enzyme that plays an important role in controlling inflammation and immune responses in the body. By inhibiting PDE-4 (Phosphodiesterase-4), roflumilast helps to reduce redness, itch, scaling, and improve other skin symptoms. Roflumilast is a phosphodiesterase 4 (PDE4) inhibitor.

Roflumilast is contraindicated in conditions like Hypersensitivity,Hepatic impairment.

Roflumilast produces potentially life-threatening effects which include Suicidal ideation. which are responsible for the discontinuation of Roflumilast therapy.The signs and symptoms that are produced after the acute overdosage of Roflumilast include Palpitations, Dizziness, Headache, GI disturbances, aterial hypotension.The symptomatic adverse reactions produced by Roflumilast are more or less tolerable and if they become severe, they can be treated symptomatically, these include Headache, Nausea, Diarrhea, Insomnia, Abdominal pain, Decreased appetite, Weight loss.

Not to be use as a rescue medicinal product for acute bronchospams, should not be gien in patient with CHF, Risk of psychiatric disorder, not recomended with theophylline, patient with glastose intolerance should not use it, patient should reduce smoking, in case of clinically decrease weight lose treatment should be stoped.

Drug should not be given to Pregnant Mothers, patients suffering from Kidney dysfunction, and patients suffering from Liver Malfunction.If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.

500 to 500 ug (500 (500)) 24 hourly PO —

No child dosage information is recorded for this medicine yet.

No neonatal dosage information is recorded for this medicine yet.

Tell your healthcare provider about the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Using roflumilast cream or foam with medicines that are systemic CYP3A4 inhibitors or dual inhibitors that inhibit both CYP3A4 and CYP1A2 simultaneously may increase the active ingredient roflumilast systemic exposure and may increase side effects. It is important to weigh up the potential for increased adverse reactions against benefit if these products are used together with Roflumilast cream or foam. Using roflumilast cream with oral contraceptives containing gestodene and ethinyl estradiol may increase roflumilast systemic exposure and may result in increased side effects. The risk of such concurrent use should be weighed carefully against the benefit. This list is not complete. Not all possible drug interactions are listed here.

No storage information is recorded for this medicine yet.